Glucosylceramide synthase decrease in frontal cortex of Alzheimer brain correlates with abnormal increase in endogenous ceramides: Consequences to morphology and viability on enzyme suppression in cultured primary neurons

Brain Research

Volumn 1191, Issue , 2008, Pages 136-147

  Marks, Neville ^a,b   Berg, Martin J ^a   Saito, Mariko ^a,b   Saito, Mitsuo ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Ceramide; Cerebellar granule cells; Glucosylceramide synthase; P4 inhibitor; Primary neurons

Indexed keywords

ACETIC ACID; CARBON 14; CASPASE; CASPASE 2; CASPASE 8; CERAMIDE DERIVATIVE; CERAMIDE GLUCOSYLTRANSFERASE; FLUORESCENT DYE; GALACTOSE; SPHINGOLIPID; SYNAPTOPHYSIN; THREONINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CULTURE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; ENZYME REPRESSION; FRONTAL CORTEX; GRANULE CELL; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NERVE CELL; NEURITE; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; CASE-CONTROL STUDIES; CELLS, CULTURED; CERAMIDES; CEREBELLUM; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; FRONTAL LOBE; GLUCOSYLTRANSFERASES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATCHED-PAIR ANALYSIS; NEURITES; PROPANOLAMINES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; SPHINGOLIPIDS;

EID: 38349051098     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.10.066     Document Type: Article

References (77)

1. Abe A., Radin N.S., Shayman J.A., Wotring L.L., Zipkin R.E., Sivakumar R., Ruggieri J.M., Carson K.G., and Ganem B. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J. Lipid Res. 36 (1995) 611-621
2. 2-ceramides. J. Biol. Chem. 271 (1996) 14383-14389
3. Abe A., Gregory S., Lee L., and Shayman J.A. Use of sulfobutyl ether beta-cyclodextrin as a vehicle for d-threo-1-phenyl-2-decanoylamino-3-morpholinopropanol-related glucosylceramide synthase inhibitors. Anal. Biochem. 287 (2000) 344-347
4. Babia T., Ledesma M.D., Saffrich R., Kok J.W., Dotti C.G., and Egea G. Endocytosis of NBD-sphingolipids in neurons: exclusion from degradative compartments and transport to the Golgi complex. Traffic 2 (2001) 395-405
5. Balazs R., Gallo V., and Kingsbury A. Effect of depolarization on the maturation of cerebellar granule cells in culture. Brain Res. 468 (1988) 269-276
6. 1 ganglioside. Alcohol Clin. Exp. Res. 21 (1997) 1199-1203
7. Basha M.R., Wei W., Bakheet S.A., Benitez N., Siddiqi H.K., Ge Y.W., Lahiri D.K., and Zawia N.H. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J. Neurosci. 25 (2005) 823-829
8. Belaud-Rotureau M.A., Lacombe F., Durrieu F., Vial J.P., Lacoste L., Bernard P., and Belloc F. Ceramide-induced apoptosis occurs independently of caspases and is decreased by leupeptin. Cell Death Differ. 6 (1999) 788-795
9. Braak H., and Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1 (1991) 213-216
10. Buccoliero R., and Futerman A.H. The roles of ceramide and complex sphingolipids in neuronal cell function. Pharmacol. Res. 47 (2003) 409-419
11. Castro-Obregon S., Rao R.V., del R.G., Chen S.F., Poksay K.S., Rabizadeh S., Vesce S., Zhang X.K., Swanson R.A., and Bredesen D.E. Alternative, nonapoptotic programmed cell death: mediation by arrestin 2, ERK2, and Nur77. J. Biol. Chem. 279 (2004) 17543-17553
12. Copani A., Melchiorri D., Caricasole A., Martini F., Sale P., Carnevale R., Gradini R., Sortino M.A., Lenti L., De Maria R., and Nicoletti F. Beta-amyloid-induced synthesis of the ganglioside GD3 is a requisite for cell cycle reactivation and apoptosis in neurons. J. Neurosci. 22 (2002) 3963-3968
13. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., Troncoso J.C., and Mattson M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 2070-2075
14. D'Angelo G., Polishchuk E., Di T.G., Santoro M., Di C.A., Godi A., West G., Bielawski J., Chuang C.C., van der Spoel A.C., Platt F.M., Hannun Y.A., Polishchuk R., Mattjus P., and De Matteis M.A. Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature 449 (2007) 62-67
15. + deprivation. J. Neurochem. 70 (1998) 1809-1818
16. de Chaves E.P., Bussiere M., MacInnis B., Vance D.E., Campenot R.B., and Vance J.E. Ceramide inhibits axonal growth and nerve growth factor uptake without compromising the viability of sympathetic neurons. J. Biol. Chem. 276 (2001) 36207-36214
17. Farooqui A.A., Horrocks L.A., and Farooqui T. Interactions between neural membrane glycerophospholipid and sphingolipid mediators: a recipe for neural cell survival or suicide. J. Neurosci. Res. 85 (2007) 1834-1850
18. Folkesson R., Malkiewicz K., Kloskowska E., Nilsson T., Popova E., Bogdanovic N., Ganten U., Ganten D., Bader M., Winblad B., and Benedikz E. A transgenic rat expressing human APP with the Swedish Alzheimer's disease mutation. Biochem. Biophys. Res. Commun. 358 (2007) 777-782
19. Goswami R., and Dawson G. Does ceramide play a role in neural cell apoptosis?. J. Neurosci. Res. 60 (2000) 141-149
20. Grassme H., Jekle A., Riehle A., Schwarz H., Berger J., Sandhoff K., Kolesnick R., and Gulbins E. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem. 276 (2001) 20589-20596
21. Han X. Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2 (2005) 65-77
22. Han X., Holtzman D.M., and McKeel Jr. D.W. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J. Neurochem. 77 (2001) 1168-1180
23. Han X., Holtzman M., McKeel Jr. D.W., Kelley J., and Morris J.C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 82 (2002) 809-818
24. Hannun Y.A., and Obeid L.M. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J. Biol. Chem. 277 (2002) 25847-25850
25. Haughey N.J., Cutler R.G., Tamara A., McArthur J.C., Vargas D.L., Pardo C.A., Turchan J., Nath A., and Mattson M.P. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann. Neurol. 55 (2004) 257-267
26. Hayashi Y., Horibata Y., Sakaguchi K., Okino N., and Ito M. A sensitive and reproducible assay to measure the activity of glucosylceramide synthase and lactosylceramide synthase using HPLC and fluorescent substrates. Anal. Biochem. 345 (2005) 181-186
27. Hofmann K., and Dixit V.M. Ceramide in apoptosis-does it really matter?. Trends Biochem. Sci. 23 (1998) 374-377
28. Huitema K., Van Den D.J., Brouwers J.F., and Holthuis J.C. Identification of a family of animal sphingomyelin synthases. EMBO J. 23 (2004) 33-44
29. Irie F., and Hirabayashi Y. Application of exogenous ceramide to cultured rat spinal motoneurons promotes survival or death by regulation of apoptosis depending on its concentrations. J. Neurosci. Res. 54 (1998) 475-485
30. Jaffrezou J.P., Chen G., Duran G.E., Muller C., Bordier C., Laurent G., Sikic B.I., and Levade T. Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. Biochim. Biophys. Acta 1266 (1995) 1-8
31. Jennemann R., Sandhoff R., Wang S., Kiss E., Gretz N., Zuliani C., Martin-Villalba A., Jager R., Schorle H., Kenzelmann M., Bonrouhi M., Wiegandt H., and Grone H.J. Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 12459-12464
32. Katsel P., Li C., and Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?. Neurochem. Res. 32 (2007) 845-856
33. Kim W.H., Choi C.H., Kang S.K., Kwon C.H., and Kim Y.K. Ceramide induces non-apoptotic cell death in human glioma cells. Neurochem. Res. 30 (2005) 969-979
34. 6-NBD-glucosylceramide, is subject to extensive degradation in the plasma membrane: implications for signal transduction related to cell differentiation. Biochem. J. 309 (1995) 905-912
35. Koval M., and Pagano R.E. Sorting of an internalized plasma membrane lipid between recycling and degradative pathways in normal and Niemann-Pick, type A fibroblasts. J. Cell Biol. 111 (1990) 429-442
36. 1 and other gangliosides in neuronal differentiation. Overview and new finding. Ann. N.Y. Acad. Sci. 845 (1998) 161-175
37. Lee L., Abe A., and Shayman J.A. Improved inhibitors of glucosylceramide synthase. J. Biol. Chem. 274 (1999) 14662-14669
38. Liu B., Andrieu-Abadie N., Levade T., Zhang P., Obeid L.M., and Hannun Y.A. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J. Biol. Chem. 273 (1998) 11313-11320
39. Liu Y.Y., Han T.Y., Giuliano A.E., and Cabot M.C. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J. Biol. Chem. 274 (1999) 1140-1146
40. Luberto C., Hassler D.F., Signorelli P., Okamoto Y., Sawai H., Boros E., Hazen-Martin D.J., Obeid L.M., Hannun Y.A., and Smith G.K. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J. Biol. Chem. 277 (2002) 41128-41139
41. Malisan F., and Testi R. GD3 ganglioside and apoptosis. Biochim. Biophys. Acta 1585 (2002) 179-187
42. Marks D.L., Wu K., Paul P., Kamisaka Y., Watanabe R., and Pagano R.E. Oligomerization and topology of the Golgi membrane protein glucosylceramide synthase. J. Biol. Chem. 274 (1999) 451-456
43. Marks N.B. Secretase processing of amyloid precursor protein (APP) and neurodegeneration. In: Lajtha A., and Banik N.E. (Eds). Neural Protein Metabolism and Function (2007), Springer, New York 469-514
44. Marks N., and Berg M.J. Neurosecretase characterization and trafficking provide new concepts to treat sporadic and familial Alzheimer disorders. Neurochem. Int. (2007) 10.1016/j.neuint.2007.06.020
45. Marks N., Berg M.J., Saito M., and Guidotti A. Activation of caspase-3 and apoptosis in cerebellar granule cells. J. Neurosci. Res. 52 (1998) 334-341
46. Marks N., Saito M., Green M., Reilly M.A., Yang A.J., Ditaranto K., and Berg M.J. Opposite effects of lithium on proximal and distal caspases of immature and mature primary neurons correlate with earlier paradoxical actions on viability. Neurochem. Res. 26 (2001) 1311-1320
47. Maurer B.J., Melton L., Billups C., Cabot M.C., and Reynolds C.P. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst. 92 (2000) 1897-1909
48. Melchiorri D., Martini F., Lococo E., Gradini R., Barletta E., De Maria R., Caricasole A., Nicoletti F., and Lenti L. An early increase in the disialoganglioside GD3 contributes to the development of neuronal apoptosis in culture. Cell Death Differ. 9 (2002) 609-615
49. Miguet C., Monier S., Bettaieb A., Athias A., Bessede G., Laubriet A., Lemaire S., Neel D., Gambert P., and Lizard G. Ceramide generation occurring during 7beta-hydroxycholesterol- and 7-ketocholesterol-induced apoptosis is caspase independent and is not required to trigger cell death. Cell Death Differ. 8 (2001) 83-99
50. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van B.G., and Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991) 479-486
51. Ngamukote S., Yanagisawa M., Ariga T., Ando S., and Yu R.K. Developmental changes of glycosphingolipids and expression of glycogenes in mouse brains. J. Neurochem. 103 (2007) 2327-2341
52. 2+) promotes apoptosis in newborn rat cerebellar neurons: pathological implications. J. Pharmacol. Exp. Ther. 279 (1996) 435-442
53. Okazaki T., Kondo T., Kitano T., and Tashima M. Diversity and complexity of ceramide signalling in apoptosis. Cell Signal. 10 (1998) 685-692
54. Puglielli L., Ellis B.C., Saunders A.J., and Kovacs D.M. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J. Biol. Chem. 278 (2003) 19777-19783
55. Pugliese M., Gangitano C., Ceccariglia S., Carrasco J.L., Del F.A., Rodriguez M.J., Michetti F., Mascort J., and Mahy N. Canine cognitive dysfunction and the cerebellum: acetylcholinesterase reduction, neuronal and glial changes. Brain Res. 1139 (2007) 85-94
56. Radin N.S. Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem. J. 371 (2003) 243-256
57. 4) is a major ganglioside in chicken embryonic liver. J. Lipid Res. 23 (1982) 9-13
58. Saito M., and Rosenberg A. The fate of glucosylceramide (glucocerebroside) in genetically impaired (lysosomal beta-glucosidase deficient) Gaucher disease diploid human fibroblasts. J. Biol. Chem. 260 (1985) 2295-2300
59. 20 potently protects neurons against apoptosis. Ann. N.Y. Acad. Sci. 845 (1998) 253-262
60. Saito M., Berg M.J., Guidotti A., and Marks N. Gangliosides attenuate ethanol-induced apoptosis in cerebellar granule neurons. J. Neurochem. Res. 24 (1999) 1109-1117
61. Sawai H., Domae N., and Okazaki T. Current status and perspectives in ceramide-targeting molecular medicine. Curr. Pharm. Des. 11 (2005) 2479-2487
62. Schwarz A., and Futerman A.H. Distinct roles for ceramide and glucosylceramide at different stages of neuronal growth. J. Neurosci. 17 (1997) 2929-2938
63. Selkoe D.J. Alzheimer's disease is a synaptic failure. Science 298 (2002) 789-791
64. Selvam R., and Radin N.S. Quantitation of lipids by charring on thin-layer plates and scintillation quenching: application to ceramide determination. Anal. Biochem. 112 (1981) 338-345
65. Shabbits J.A., and Mayer L.D. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim. Biophys. Acta 1612 (2003) 98-106
66. Simon Jr. C.G., Holloway P.W., and Gear A.R. Exchange of C(16)-ceramide between phospholipid vesicles. Biochemistry 38 (1999) 14676-14682
67. Sjobeck M., and Englund E. Alzheimer's disease and the cerebellum: a morphologic study on neuronal and glial changes. Dement. Geriatr. Cogn. Disord. 12 (2001) 211-218
68. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., and Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150 (1985) 76-85
69. Sperandio S., Poksay K., de B.I., Lafuente M.J., Liu B., Nasir J., and Bredesen D.E. Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ. 11 (2004) 1066-1075
70. Stoica B.A., Movsesyan V.A., Lea P.M., and Faden A.I. Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3beta, and induction of the mitochondrial-dependent intrinsic caspase pathway. Mol. Cell. Neurosci. 22 (2003) 365-382
71. Svennerholm L., Brane G., Karlsson I., Lekman A., Ramstrom I., and Wikkelso C. Alzheimer disease - effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme. Dement. Geriatr. Cogn. Disord. 14 (2002) 128-136
72. Tamboli I.Y., Prager K., Barth E., Heneka M., Sandhoff K., and Walter J. Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J. Biol. Chem. 280 (2005) 28110-28117
73. Tepper A.D., de Vries E., van Blitterswijk W.J., and Borst J. Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage-induced apoptosis. J. Clin. Invest 103 (1999) 971-978
74. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., and Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30 (1991) 572-580
75. Van Vickle G.D., Esh C.L., Kalback W.M., Patton R.L., Luehrs D.C., Kokjohn T.A., Fifield F.G., Fraser P.E., Westaway D., McLaurin J., Lopez J., Brune D., Newel A.J., Poston M., Beach T.G., and Roher A.E. TgCRND8 amyloid precursor protein transgenic mice exhibit an altered gamma-secretase processing and an aggressive, additive amyloid pathology subject to immunotherapeutic modulation. Biochemistry 46 (2007) 10317-10327
76. Wegiel J., Wisniewski H.M., Dziewiatkowski J., Badmajew E., Tarnawski M., Reisberg B., Mlodzik B., De Leon M.J., and Miller D.C. Cerebellar atrophy in Alzheimer's disease-clinicopathological correlations. Brain Res. 818 (1999) 41-50
77. Yamashita T., Wada R., Sasaki T., Deng C., Bierfreund U., Sandhoff K., and Proia R.L. A vital role for glycosphingolipid synthesis during development and differentiation. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 9142-9147